Global Botanical and Plant-Derived Drugs
Global Botanical and Plant-Derived Drugs

Botanical and Plant-Derived Drugs Comprehensive Study by Type (Terpenes, Steroids, Glycosides, Phenols), Application (Oncology, Dermatology, CNS disorders, Hormone diseases) Players and Region - Global Market Outlook to 2026

Botanical and Plant-Derived Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 200 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Botanical and Plant-Derived Drugs Market Overview:
Botanical and plant derivative drugs are used to treat a variety of diseases, including central nervous system disorders, infectious diseases, cardiovascular diseases, and respiratory diseases. Botanical and plant derivative drugs come in a variety of forms, including pills, tablets, and injections. Plants are used to make botanical drugs such as atropine, aescin, and berberine, as well as Adonis ide.

Growth Drivers
  • Growing applications in diseases
  • Growing focus on natural source medicines
  • Growing demand for effective treatment of chronic disorders

Roadblocks
  • High cost of research and development, and stringent government regulations towards product
  • High cost of specialty drugs

Opportunities
  • Increasing awareness of growing technological innovation

Challenges
  • Increasing number of diseases


Competitive Landscape:
Companies in the market are concentrating on the drugs and healthcare industry. North America and Europe witnessed the largest growing region due to rising awareness towards botanical and plant-derived drugs and increasing prevalence of diseases, technological advancement in the production procedure of botanical is also supporting the growth of botanical and plant-derived drugs in these regions.
Some of the key players profiled in the report are Abbott Laboratories (U.S.), Eli Lilly (U.S.), Medigene (Germany), Pfizer (U.S.), Lupin Ltd. (India), Johnson & Johnson (U.S.), Novartis International AG (Switzerland), Glaxosmithkline (UK) and Leo Pharma (Denmark). Analyst at AMA Research see United States Players to retain maximum share of Global Botanical and Plant-Derived Drugs market by 2026. Considering Market by Type, the sub-segment i.e. Terpenes will boost the Botanical and Plant-Derived Drugs market. Considering Market by Application, the sub-segment i.e. Oncology will boost the Botanical and Plant-Derived Drugs market.

2 Sep 2021: Abbott acquired Walk Vascular, LLC. This acquisition expanded peripheral vascular offering to remove peripheral blood clots.

What Can be Explored with the Botanical and Plant-Derived Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Botanical and Plant-Derived Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Botanical and Plant-Derived Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Botanical and Plant-Derived Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Botanical and Plant-Derived Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Research & Development, Healthcare & Pharmaceutical Industry, End-User Industry and Government & Public Sectors.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Botanical and Plant-Derived Drugs Market?
The Botanical and Plant-Derived Drugs market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Botanical and Plant-Derived Drugs Market?
Top performing companies in the Global Botanical and Plant-Derived Drugs market are Abbott Laboratories (U.S.), Eli Lilly (U.S.), Medigene (Germany), Pfizer (U.S.), Lupin Ltd. (India), Johnson & Johnson (U.S.), Novartis International AG (Switzerland), Glaxosmithkline (UK) and Leo Pharma (Denmark), to name a few.

3. What trending factors would impact Botanical and Plant-Derived Drugs Market growth most?
"Increase in number of research and development in the pharmaceutical industry " is seen as one of major influencing trends for Botanical and Plant-Derived Drugs Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Type
  • Terpenes
  • Steroids
  • Glycosides
  • Phenols

By Application
  • Oncology
  • Dermatology
  • CNS disorders
  • Hormone diseases

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing applications in diseases
      • 3.2.2. Growing focus on natural source medicines
      • 3.2.3. Growing demand for effective treatment of chronic disorders
    • 3.3. Market Challenges
      • 3.3.1. Increasing number of diseases
    • 3.4. Market Trends
      • 3.4.1. Increase in number of research and development in the pharmaceutical industry
      • 3.4.2. An increasing number of mergers and acquisitions by manufacturing companies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Botanical and Plant-Derived Drugs, by Type, Application and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Botanical and Plant-Derived Drugs (Value)
      • 5.2.1. Global Botanical and Plant-Derived Drugs by: Type (Value)
        • 5.2.1.1. Terpenes
        • 5.2.1.2. Steroids
        • 5.2.1.3. Glycosides
        • 5.2.1.4. Phenols
      • 5.2.2. Global Botanical and Plant-Derived Drugs by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Dermatology
        • 5.2.2.3. CNS disorders
        • 5.2.2.4. Hormone diseases
      • 5.2.3. Global Botanical and Plant-Derived Drugs by: Type (Value)
        • 5.2.3.1. Terpenes
        • 5.2.3.2. Steroids
        • 5.2.3.3. Glycosides
        • 5.2.3.4. Phenols
      • 5.2.4. Global Botanical and Plant-Derived Drugs by: Application (Value)
        • 5.2.4.1. Oncology
        • 5.2.4.2. Dermatology
        • 5.2.4.3. CNS disorders
        • 5.2.4.4. Hormone diseases
      • 5.2.5. Global Botanical and Plant-Derived Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Botanical and Plant-Derived Drugs (Price)
  • 6. Botanical and Plant-Derived Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (U.S.)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly (U.S.)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Medigene (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (U.S.)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Lupin Ltd. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (U.S.)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis International AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Glaxosmithkline (UK)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Leo Pharma (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Botanical and Plant-Derived Drugs Sale, by Type, Application and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Botanical and Plant-Derived Drugs (Value)
      • 7.2.1. Global Botanical and Plant-Derived Drugs by: Type (Value)
        • 7.2.1.1. Terpenes
        • 7.2.1.2. Steroids
        • 7.2.1.3. Glycosides
        • 7.2.1.4. Phenols
      • 7.2.2. Global Botanical and Plant-Derived Drugs by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Dermatology
        • 7.2.2.3. CNS disorders
        • 7.2.2.4. Hormone diseases
      • 7.2.3. Global Botanical and Plant-Derived Drugs by: Type (Value)
        • 7.2.3.1. Terpenes
        • 7.2.3.2. Steroids
        • 7.2.3.3. Glycosides
        • 7.2.3.4. Phenols
      • 7.2.4. Global Botanical and Plant-Derived Drugs by: Application (Value)
        • 7.2.4.1. Oncology
        • 7.2.4.2. Dermatology
        • 7.2.4.3. CNS disorders
        • 7.2.4.4. Hormone diseases
      • 7.2.5. Global Botanical and Plant-Derived Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Botanical and Plant-Derived Drugs (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Botanical and Plant-Derived Drugs: by Type(USD Million)
  • Table 2. Botanical and Plant-Derived Drugs Terpenes , by Region USD Million (2015-2020)
  • Table 3. Botanical and Plant-Derived Drugs Steroids , by Region USD Million (2015-2020)
  • Table 4. Botanical and Plant-Derived Drugs Glycosides , by Region USD Million (2015-2020)
  • Table 5. Botanical and Plant-Derived Drugs Phenols , by Region USD Million (2015-2020)
  • Table 6. Botanical and Plant-Derived Drugs: by Application(USD Million)
  • Table 7. Botanical and Plant-Derived Drugs Oncology , by Region USD Million (2015-2020)
  • Table 8. Botanical and Plant-Derived Drugs Dermatology , by Region USD Million (2015-2020)
  • Table 9. Botanical and Plant-Derived Drugs CNS disorders , by Region USD Million (2015-2020)
  • Table 10. Botanical and Plant-Derived Drugs Hormone diseases , by Region USD Million (2015-2020)
  • Table 11. Botanical and Plant-Derived Drugs: by Type(USD Million)
  • Table 12. Botanical and Plant-Derived Drugs Terpenes , by Region USD Million (2015-2020)
  • Table 13. Botanical and Plant-Derived Drugs Steroids , by Region USD Million (2015-2020)
  • Table 14. Botanical and Plant-Derived Drugs Glycosides , by Region USD Million (2015-2020)
  • Table 15. Botanical and Plant-Derived Drugs Phenols , by Region USD Million (2015-2020)
  • Table 16. Botanical and Plant-Derived Drugs: by Application(USD Million)
  • Table 17. Botanical and Plant-Derived Drugs Oncology , by Region USD Million (2015-2020)
  • Table 18. Botanical and Plant-Derived Drugs Dermatology , by Region USD Million (2015-2020)
  • Table 19. Botanical and Plant-Derived Drugs CNS disorders , by Region USD Million (2015-2020)
  • Table 20. Botanical and Plant-Derived Drugs Hormone diseases , by Region USD Million (2015-2020)
  • Table 21. South America Botanical and Plant-Derived Drugs, by Country USD Million (2015-2020)
  • Table 22. South America Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 23. South America Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 24. Brazil Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 25. Brazil Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 26. Argentina Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 27. Argentina Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 29. Rest of South America Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Botanical and Plant-Derived Drugs, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 33. China Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 34. China Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 35. Japan Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 36. Japan Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 37. India Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 38. India Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 39. South Korea Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 40. South Korea Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 41. Taiwan Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 42. Taiwan Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 43. Australia Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 44. Australia Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 45. Rest of Asia-Pacific Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 47. Europe Botanical and Plant-Derived Drugs, by Country USD Million (2015-2020)
  • Table 48. Europe Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 49. Europe Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 50. Germany Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 51. Germany Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 52. France Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 53. France Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 54. Italy Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 55. Italy Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 56. United Kingdom Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 57. United Kingdom Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 58. Netherlands Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 59. Netherlands Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 60. Rest of Europe Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 61. Rest of Europe Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 62. MEA Botanical and Plant-Derived Drugs, by Country USD Million (2015-2020)
  • Table 63. MEA Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 64. MEA Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 65. Middle East Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 66. Middle East Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 67. Africa Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 68. Africa Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 69. North America Botanical and Plant-Derived Drugs, by Country USD Million (2015-2020)
  • Table 70. North America Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 71. North America Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 72. United States Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 73. United States Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 74. Canada Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 75. Canada Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 76. Mexico Botanical and Plant-Derived Drugs, by Type USD Million (2015-2020)
  • Table 77. Mexico Botanical and Plant-Derived Drugs, by Application USD Million (2015-2020)
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Company Basic Information, Sales Area and Its Competitors
  • Table 84. Company Basic Information, Sales Area and Its Competitors
  • Table 85. Company Basic Information, Sales Area and Its Competitors
  • Table 86. Company Basic Information, Sales Area and Its Competitors
  • Table 87. Botanical and Plant-Derived Drugs: by Type(USD Million)
  • Table 88. Botanical and Plant-Derived Drugs Terpenes , by Region USD Million (2021-2026)
  • Table 89. Botanical and Plant-Derived Drugs Steroids , by Region USD Million (2021-2026)
  • Table 90. Botanical and Plant-Derived Drugs Glycosides , by Region USD Million (2021-2026)
  • Table 91. Botanical and Plant-Derived Drugs Phenols , by Region USD Million (2021-2026)
  • Table 92. Botanical and Plant-Derived Drugs: by Application(USD Million)
  • Table 93. Botanical and Plant-Derived Drugs Oncology , by Region USD Million (2021-2026)
  • Table 94. Botanical and Plant-Derived Drugs Dermatology , by Region USD Million (2021-2026)
  • Table 95. Botanical and Plant-Derived Drugs CNS disorders , by Region USD Million (2021-2026)
  • Table 96. Botanical and Plant-Derived Drugs Hormone diseases , by Region USD Million (2021-2026)
  • Table 97. Botanical and Plant-Derived Drugs: by Type(USD Million)
  • Table 98. Botanical and Plant-Derived Drugs Terpenes , by Region USD Million (2021-2026)
  • Table 99. Botanical and Plant-Derived Drugs Steroids , by Region USD Million (2021-2026)
  • Table 100. Botanical and Plant-Derived Drugs Glycosides , by Region USD Million (2021-2026)
  • Table 101. Botanical and Plant-Derived Drugs Phenols , by Region USD Million (2021-2026)
  • Table 102. Botanical and Plant-Derived Drugs: by Application(USD Million)
  • Table 103. Botanical and Plant-Derived Drugs Oncology , by Region USD Million (2021-2026)
  • Table 104. Botanical and Plant-Derived Drugs Dermatology , by Region USD Million (2021-2026)
  • Table 105. Botanical and Plant-Derived Drugs CNS disorders , by Region USD Million (2021-2026)
  • Table 106. Botanical and Plant-Derived Drugs Hormone diseases , by Region USD Million (2021-2026)
  • Table 107. South America Botanical and Plant-Derived Drugs, by Country USD Million (2021-2026)
  • Table 108. South America Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 109. South America Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 110. Brazil Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 111. Brazil Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 112. Argentina Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 113. Argentina Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 114. Rest of South America Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 115. Rest of South America Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 116. Asia Pacific Botanical and Plant-Derived Drugs, by Country USD Million (2021-2026)
  • Table 117. Asia Pacific Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 118. Asia Pacific Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 119. China Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 120. China Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 121. Japan Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 122. Japan Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 123. India Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 124. India Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 125. South Korea Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 126. South Korea Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 127. Taiwan Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 128. Taiwan Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 129. Australia Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 130. Australia Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 131. Rest of Asia-Pacific Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 132. Rest of Asia-Pacific Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 133. Europe Botanical and Plant-Derived Drugs, by Country USD Million (2021-2026)
  • Table 134. Europe Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 135. Europe Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 136. Germany Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 137. Germany Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 138. France Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 139. France Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 140. Italy Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 141. Italy Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 142. United Kingdom Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 143. United Kingdom Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 144. Netherlands Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 145. Netherlands Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 146. Rest of Europe Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 147. Rest of Europe Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 148. MEA Botanical and Plant-Derived Drugs, by Country USD Million (2021-2026)
  • Table 149. MEA Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 150. MEA Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 151. Middle East Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 152. Middle East Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 153. Africa Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 154. Africa Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 155. North America Botanical and Plant-Derived Drugs, by Country USD Million (2021-2026)
  • Table 156. North America Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 157. North America Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 158. United States Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 159. United States Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 160. Canada Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 161. Canada Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 162. Mexico Botanical and Plant-Derived Drugs, by Type USD Million (2021-2026)
  • Table 163. Mexico Botanical and Plant-Derived Drugs, by Application USD Million (2021-2026)
  • Table 164. Research Programs/Design for This Report
  • Table 165. Key Data Information from Secondary Sources
  • Table 166. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Botanical and Plant-Derived Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Botanical and Plant-Derived Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Botanical and Plant-Derived Drugs: by Type USD Million (2015-2020)
  • Figure 7. Global Botanical and Plant-Derived Drugs: by Application USD Million (2015-2020)
  • Figure 8. South America Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 9. Asia Pacific Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 10. Europe Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 11. MEA Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 12. North America Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 13. Global Botanical and Plant-Derived Drugs share by Players 2020 (%)
  • Figure 14. Global Botanical and Plant-Derived Drugs share by Players (Top 3) 2020(%)
  • Figure 15. Global Botanical and Plant-Derived Drugs share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (U.S.) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (U.S.) Revenue: by Geography 2020
  • Figure 19. Eli Lilly (U.S.) Revenue, Net Income and Gross profit
  • Figure 20. Eli Lilly (U.S.) Revenue: by Geography 2020
  • Figure 21. Medigene (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Medigene (Germany) Revenue: by Geography 2020
  • Figure 23. Pfizer (U.S.) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (U.S.) Revenue: by Geography 2020
  • Figure 25. Lupin Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 26. Lupin Ltd. (India) Revenue: by Geography 2020
  • Figure 27. Johnson & Johnson (U.S.) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson (U.S.) Revenue: by Geography 2020
  • Figure 29. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 31. Glaxosmithkline (UK) Revenue, Net Income and Gross profit
  • Figure 32. Glaxosmithkline (UK) Revenue: by Geography 2020
  • Figure 33. Leo Pharma (Denmark) Revenue, Net Income and Gross profit
  • Figure 34. Leo Pharma (Denmark) Revenue: by Geography 2020
  • Figure 35. Global Botanical and Plant-Derived Drugs: by Type USD Million (2021-2026)
  • Figure 36. Global Botanical and Plant-Derived Drugs: by Application USD Million (2021-2026)
  • Figure 37. Global Botanical and Plant-Derived Drugs: by Type USD Million (2021-2026)
  • Figure 38. Global Botanical and Plant-Derived Drugs: by Application USD Million (2021-2026)
  • Figure 39. South America Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 40. Asia Pacific Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 41. Europe Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 42. MEA Botanical and Plant-Derived Drugs Share (%), by Country
  • Figure 43. North America Botanical and Plant-Derived Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (U.S.)
  • Eli Lilly (U.S.)
  • Medigene (Germany)
  • Pfizer (U.S.)
  • Lupin Ltd. (India)
  • Johnson & Johnson (U.S.)
  • Novartis International AG (Switzerland)
  • Glaxosmithkline (UK)
  • Leo Pharma (Denmark)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation